No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MREO240517C3000
- 0.13
- -0.17-56.67%
15min DelayClose May 17 15:57 ET
0.15High0.12Low
0.15Open0.30Pre Close9 Volume0 Open Interest3.00Strike Price125.00Turnover0.00%IV0.00%PremiumMay 17, 2024Expiry Date0.20Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma16.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Friday morning, rising 0.29% to 1,426.43 on the S&P Europe Select ADR Index. The index is set to c
Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending moderately lower late Thursday morning, declining 0.61% to 1,426.72 on the S&P Europe Select ADR Index. From continenta
Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (LUCY), Rockwell Med (RMTI) and Mereo Biopharma Group Plc (MREO)
Express News | Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
$SPDR S&P Biotech ETF(XBI.US$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
13
1
Read more